Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Etilevodopa,Carbidopa
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Clintrex Research Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
SynAgile Completes Enrollment of its Phase 2 Clinical Trial of its DopaFuse Delivery System
Details : The DopaFuse Delivery System is a patented, intra-oral system that continuously and noninvasively delivers levodopa and carbidopa at a controlled rate for patients with PD.
Product Name : DopaFuse
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 09, 2022
Lead Product(s) : Etilevodopa,Carbidopa
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Clintrex Research Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Etilevodopa,Carbidopa
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
First Patient Treated with the DopaFuse® Delivery System
Details : The DopaFuse System consists of an oral retainer, its case, and a prefilled, single-use drug container that continuously releases an investigational levodopa and carbidopa paste in the back of the mouth.
Product Name : DopaFuse
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 27, 2021
Lead Product(s) : Etilevodopa,Carbidopa
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable